• News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • News
  • Stock Screener
  • Small Caps
  • Guru Portfolios
  • Review
  • X (Twitter)
  • LinkedIn
Stock Screener·Taiwan·Healthcare·6879.TWO
Share

TCI GENE Inc. Stocks

NT$ 34Last Updated 29.07.2026

Issuer Rating

3/7
Performance

Favourable

Risk

High

Recommendation

Sell

Market Cap

NT$ 27.83M

NT$ 34
Key Takeaways

Risk factor

Very high price volatility

Data is available to registered users only
Data is available to registered users only

Profitability factor

Solid dividends

Data is available to registered users only
Data is available to registered users only
Sign up to get free access to key risk and return factors, detailed company valuation, and analyst forecasts
Sign up to access all the key risk and return factors

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

About

TCI GENE Inc., based in Taipei, Taiwan, specializes in delivering personalized preventative healthcare solutions. The company offers an extensive range of genetic screenings, including tests for nutrient metabolism, weight management, and specific G2 and ACE2 markers. Its diverse product portfolio encompasses dietary supplements, skincare items, anti-aging treatments, products designed to support children's development, and solutions targeting Alzheimer's disease. Additionally, TCI GENE provides specialized serums for DNA typing and offers professional nutrition counseling services.

Company Valuation

Slightly undervalued
5/7

From both historical and forecast perspectives, the stock is moderately underpriced compared to similar stocks. Specifically, the stock is fairly valued on P/E, overvalue

Data is available to registered users only
Sign up to access detailed valuation

Risks

  • Default risk
    Data is available to registered users only
  • Volatility
    Data is available to registered users only
  • Selling difficulty
    Data is available to registered users only
  • Stress test
    Data is available to registered users only
  • Country risks
    Data is available to registered users only
  • Other risks
    Data is available to registered users only
Sign up to access detailed risk analysis

Trending

31.07.2026 03:07

Apple shares fell after a weak forecast. Sales will be affected by a shortage of memory chips

31.07.2026 02:45

It's the best day for chipmakers since 2025. Burry is shorting them again.

31.07.2026 01:43

Amazon reported accelerated revenue growth in its cloud business. Its stock jumped 9%.

31.07.2026 01:27

Microsoft Beat Nvidia's Record for Market Capitalization Growth

31.07.2026 01:08

The assets of the "AI-Nostradamus" fund fell to $10 billion following the sale of part of its portfolio

X-channel

Buy

Sell

0 more stocks

Company

  • About
  • Contributors
  • Contacts
  • Legal Information

Social media

  • X (Twitter)
  • LinkedIn

Services

  • Stock Screener
  • Guru Portfolios
  • X (Twitter)
  • LinkedIn
Oninvest© 2026